TabletLinagliptin 5mg
Linagliptin
DPP-4 inhibitor unique for its non-renal elimination, requiring no dose adjustment in any degree of renal impairment. Manufactured by Cipla and Glenmark for diabetology export.
Strengths
5mg
Packing
10 tablets/strip
Origin
India (WHO-GMP)
MOQ
100 units
Export Price
On Request
Availability
In Stock
Product Specifications
Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.
Related Products
TabletGlimepiride 2mg
Glimepiride
Third-generation sulfonylurea that stimulates pancreatic beta-cell insulin secretion via selective SUR1 receptor binding, offering a lower hypoglycemia risk compared to earlier sulfonylureas due to glucose-dependent activity. The most cost-effective oral antidiabetic agent in its class and a cornerstone of type 2 diabetes management in emerging markets.
TabletSitagliptin 100mg
Sitagliptin Phosphate
First-in-class DPP-4 inhibitor that amplifies incretin-mediated glucose-dependent insulin secretion while suppressing glucagon, offering glycemic control without weight gain or intrinsic hypoglycemia risk. Once-daily dosing, renal dose adjustment flexibility, and a decade-long cardiovascular safety record make it a globally preferred add-on antidiabetic.
TabletVildagliptin 50mg
Vildagliptin
Selective DPP-4 inhibitor with potent enzyme inhibition that improves glycemic control through enhanced incretin-mediated insulin secretion and suppressed post-meal glucagon release. Widely prescribed as a fixed-dose combination with metformin (Galvusmet) offering convenient dual-mechanism therapy without weight gain.
Need bulk pricing for Linagliptin 5mg?
Send us your quantity requirements and destination country for a custom quotation.
Get Bulk Quote